Pulmatrix announces positive top-line preliminary results from phase 1/1b clinical trial
Pulmatrix announced that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for treatment of ABPA in patients with asthma. July 17, 2018